Mild presentation of systemic lupus erythematosus in elderly patients                 assessed by SLEDAI

Formiga, F; Moga, I; Pac, M.; Mitjavila, Francesca; Rivera, Alberto; Pujol, Ramón

doi:10.1177/096120339900800609

Cited by 107 publications

(109 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Age and gender of all above groups had no statistically significant difference. The active disease stage of each patient was determined according to the SLE Disease Activity Index (SLEDAI), with an SLEDAI >10 indicating the active stage (10). The concentration of total IgG in the CSF of cases with NPSLE was obtained from patient medical records.…”

Section: Patientsmentioning

confidence: 99%

Elevated levels of soluble fractalkine and increased expression of CX3CR1 in neuropsychiatric systemic lupus erythematosus

Guo

Wang

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The aim of the present study was to determine the levels of soluble fractalkine (sFKN) and expression of CX3CR1 in neuropsychiatric systemic lupus erythematosus (NPSLE). Disease activity of SLE was assessed using the SLE Disease Activity Index (SLEDAI). The mRNA expression levels of CX3CR1 and FKN were quantified using reverse transcription-quantitative polymerase chain reaction. Levels of sFKN in the serum and cerebrospinal fluid (CSF) were measured using enzyme-linked immunosorbent assays. The mRNA expression levels of CX3CR1 in peripheral blood mononuclear cells from patients with NPSLE, non-NPSLE and Behcet's disease were significantly higher than that of rheumatoid arthritis and healthy persons. Levels of sFKN in the serum and CSF of cells with diffuse NPSLE (DNPSLE) were significantly higher than those of focal NPSLE (FNPSLE) cells. Serum levels of sFKN were higher in patients with NPSLE or non-NPSLE than heathy persons. sFKN in CSF were significantly higher in DNPSLE than non-NPSLE cells, but there were no significant difference between FNPSLE and control. Treatment reduced sFKN in serum and CSF in patients with NPSLE. There was significant correlation between sFKN in the serum of patients with SLE and the SLEDAI. sFKN levels were correlated with IgG in CSF from patients with NPSLE. The mRNA expression levels of CX3CR1 in the brain tissue of lupus mice were significantly higher than normal mice; however, the mRNA expression of FKN was lower than normal mice. These results suggest that sFKN and CX3CR1 may be involved in vasculitis and SLE, particularly in DNPSLE, which may occur by damaging the blood-brain barrier or recruiting expression microglial cells of CX3CR1. Additionally, sFKN appears to be a serological marker in patients with SLE, and may be useful for the diagnosis and treatment of NPSLE.

show abstract

Section: Patientsmentioning

confidence: 99%

Elevated levels of soluble fractalkine and increased expression of CX3CR1 in neuropsychiatric systemic lupus erythematosus

Guo

Wang

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…They have less organ systems involved, and the disease is mild in them, but the progress and natural course, for some unknown reasons, is bad [100][101][102][103][104][105][106][107][108].…”

Section: Progression Of the Diseasementioning

confidence: 99%

Introduction and Physiology of Lupus

Zaman¹

2017

Lupus

View full text Add to dashboard Cite

“…Podaci iz literature koji se odnose na kliničke manifestacije Sle sa kasnim početkom veoma se razlikuju (tabela 1). Međutim, u većini studija je pokazano da je učestalost nefritisa, lupusa centralnog nervnog sistema (CNS) i kožnih manifestacija manja u grupi bolesnika sa kasnim početkom bolesti (6,(9)(10)(11). Za razliku od toga, u pojedinim studijama kožne, bubrežne i CNS manifestacije lupusa bile su podjednako zastupljene kod bolesnika sa kasnim početkom Sle kao i kod onih sa početkom bolesti u ranijim godinama života (12).…”

Section: Kliničke Manifestacijeunclassified

“…u nekim istraživanjima pokazalo se da je na početku bolesti, kao i u toku prve godine trajanja bolesti, Sledai skor nižih vrednosti kod bolesnika sa kasnim početkom oboljenja, što ukazuje na benigniji tok bolesti (11,19). Za razliku od toga drugi autori nalaze veći indeks aktivnosti Sle kod bolesnika sa kasnim početkom bolesti (10).…”

Section: Aktivnost Sle I Stepen Oštećenja Tkivaunclassified

“…S obzirom na spor nastanak i često nespecifične manifestacije na početku bolesti i manju prevalencu Sle u starijoj populaciji, kasno postavljanje dijagnoze veoma je uobičajeno u toj grupi bolesnika (21). interval od prvih manifestacija do postavljanja dijagnoze Sle znatno je duži kod bolesnika sa kasnim početkom Sle (19-50 meseci) u odnosu na bolesnike sa početkom u mlađim godinama (5-24 meseca) (2,5,11,23). takođe, u kliničkoj praksi se kod ovih bolesnika često postavlja pogrešna dijagnoza.…”

Section: Aktivnost Sle I Stepen Oštećenja Tkivaunclassified

See 1 more Smart Citation

10.5937/mckg48-6173 = Late-onset systemicus lupus erithematosus

Lucic¹

2014

Medicinski casopis

View full text Add to dashboard Cite

UVODSistemski eritemski lupus (Sle) jeste hronična autoimuna bolest, koja ima multisistemski karakter, s velikim spektrom kliničkih i laboratorijskih manifestacija. etiopatogenetski faktori koji mogu da utiču na razvoj Sle uključuju, pre svega, genetsku predispoziciju i faktore spoljašne sredine -hormone, infektivne agense, hemijske i fizičke fakltore koji su okidači početka oboljenja (1). interakcija pola, hormonskog miljea i hipotalamohipofizno-adrenalne osovine modifikuje predispoziciju i kliničku ekspresiju bolesti. genetskoj predispoziciji za Sle doprinose geni Hla klase ii -dr2 i dr3, kao i geni koji kodiraju komponente komplementa C2 i C4. Pored toga, Sle je povezan sa urođenim deficitom C1q, C1r/s i C2. Smanjenje aktivnosti komplementa utiče na neutralizaciju i klirens autoantigena i stranih antigena, što može da poveća predispoziciju za nastanak Sle (1). deficitarni imunoregulatorni mehanizmi, kao što je klirens apoptoznih ćelija i imunskih kompleksa, značajno doprinose razvoju Sle. gubitak imunske tolerancije i pojačano opterećenje antigenima, neumerena aktivnost Cd4 limfocita, smanjena B ćelijska supresija i pomeranje imunskog odgovora iz th1 u th2 profil, dovodi do hiperaktivnosti B limfocita i povećanog stvaranja patogenih antitela. u toku starenja organizma imuni sistem prolazi kroz kontinuirane morfološke i funkcionalne promene, gubeći sposobnost da se uspešno brani od stranih patogena, a za razliku od toga povećava se odgovor na autoantigene (2). Kod pripadnika zdrave starije populacije povećava se učestalost antinuklearnih antitela (aNa) i reumatoidnih faktora (rF). u toku starenja nivo serumskih citokina i reaktanata akutne faze povećava se 2-4 puta. Medijatori inflamacije (proinflamatorni citokini, histamin, prostaglandini) verovatno pretstavljaju vezu između

show abstract

Mild presentation of systemic lupus erythematosus in elderly patients assessed by SLEDAI

Abstract: Our results confirm using SLEDAI, that the lupus of the elderly patients is a distinct clinical subgroup with a milder course of disease.

Cited by 107 publications

References 10 publications

Elevated levels of soluble fractalkine and increased expression of CX3CR1 in neuropsychiatric systemic lupus erythematosus

Elevated levels of soluble fractalkine and increased expression of CX3CR1 in neuropsychiatric systemic lupus erythematosus

Introduction and Physiology of Lupus

10.5937/mckg48-6173 = Late-onset systemicus lupus erithematosus

Contact Info

Product

Resources

About